Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Rodman & Renshaw Reiterates Sell Rating on Cassava Sciences (SAVA), PT $2
March 25, 2025 10:05 AM EDTRodman & Renshaw analyst Elemer Piros reiterated a Sell rating and $2.00 price target on Cassava Sciences (NASDAQ: SAVA).
The analyst comments "Cassava Sciences, Inc. (SAVA; Sell) announced topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate AD. Simufilam is a proprietary,... More
Cassava Sciences (SAVA) to Resume Trading at 8:35 a.m.
March 25, 2025 8:10 AM EDTCassava Sciences (NASDAQ: SAVA) to Resume Trading at 8:35 a.m.
